explore -WSS

explore

author：explore 2025-10-01 17:06:18 - browse：289

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： FDA official pushes for dedicated emerging pathogens team

entertainment

WSS

Will.i.am, Britney Spears release new single, 'Mind Your Business'

A double vaccine crisis is endangering millions of children

A double vaccine crisis is endangering millions of children

New rules on organ donation and transplantation 'will bring chaos'

Artificial intelligence advances fuel industry trying to preserve loved ones after death

FDA official pushes for dedicated emerging pathogens team

hotspot

explore

Wikipedia

How to save PrEP access — and even expand it

Bulgari apologizes to China for listing Taiwan as a country after online backlash

United colonoscopy coverage change 'may cost lives,' doctors say

Retired US general questions alleged Putin, Prigozhin meeting

State Dept. review finds Biden bears some blame for Afghanistan failures

Elizabeth Warren probes abortion access

Jerome Adams on the need for new antivirals for Covid

FDA official pushes for dedicated emerging pathogens team

Supreme Court strikes down use of affirmative action

Our daughter's deadly disease: trisomy 18. We wanted to protect her

focus

A new study sees potential in DNA sequencing of infants

Charles Manson follower Leslie Van Houten released from prison after 53 years

It's time to get medical device identifiers over the finish line

Why an extreme heat and wildfire smoke combination can be so dangerous

Review: 'Barbie' will hit you like a shot in the heart

What to know about OceanGate, the company behind the missing Titanic submersible

focus

entertainment

leisure time

explore